Amgen Inc.

Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The company's products include: Enbrel? (etanercept), which is used in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis; and Prolia? (denosumab), which is used for the treatment of postmenopausal women with osteoporosis at high risk of fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
  • TickerAMGN
  • ISINUS0311621009
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Amgen Inc. - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

Amgen Inc. - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

AMGEN sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of AMGEN (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date January 15, 2021, the closing price was USD 245.49 and its potential was estimated at USD 264.50.

Moody's announces completion of a periodic review of ratings of Amgen Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Amgen Inc.. Global Credit Research- 15 Dec 2020. New York, December 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with the same analytical unit.

Amgen Inc. - September 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weigh...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Small-Caps Testing Critical Resistance; Downgrading Communications As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based advance. There are some developments that leave us wanting more, but we are inching toward an outright bullish outlook. • The Failure of a Bearish Pattern is Bullish. We often know the implied direction (up or down) that a specific chart pattern is likely to resolve based on historical probabilities. But chart patterns are not infallible, and some technicians - present company inclu...

MarketLine Department

Celgene Corporation - Strategy, SWOT and Corporate Finance Report

Summary Celgene Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Celgene Corporation (Celgene or 'the company') is a biopharmaceutical company that produces and sells novel therapies for the treatment of inflammatory diseases and cancer through next-generation solutions in immuno-oncology, protein homeostasis, immunology, epigenetics and neuro-inflamm...

MarketLine Department

AbbVie Inc. - Strategy, SWOT and Corporate Finance Report

Summary AbbVie Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights AbbVie Inc. (AbbVie or 'the company') is a biopharmaceutical company that discovers, develops, manufactures and commercializes drugs for the treatment of chronic and complex diseases. The company develops pharmaceutical products that mainly consist of Humira (adalimumab) and products in therapeu...

MarketLine Department

Pfizer Inc. - Strategy, SWOT and Corporate Finance Report

Summary Pfizer Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Pfizer Inc. (Pfizer or 'the company') is a research based global biopharmaceutical company. The company develops consumer healthcare products, vaccines, medicines and therapies to treat various conditions including inflammation and immunology, neuroscience and pain, cardiovascular and metabolic,...

MarketLine Department

Alexion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Alexion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Alexion Pharmaceuticals, Inc. (Alexion or 'the company') is a biopharmaceutical company involved in the innovation, development and commercialization of life-transforming therapeutic products. The company focuses on the therapeutic areas such as Neurology, Hematology, Nephrolog...

MarketLine Department

Bristol-Myers Squibb Company - Strategy, SWOT and Corporate Finance Report

Summary Bristol-Myers Squibb Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Bristol-Myers Squibb Company (BMS or 'the company') is a global biopharmaceutical company. The company is involved in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines. It develops medicines in various therapeutic area...

Amgen Inc. - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

Amgen Inc. - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's announces completion of a periodic review of ratings of Amgen Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Amgen Inc.. Global Credit Research- 15 Dec 2020. New York, December 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with the same analytical unit.

Amgen Inc. - September 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc. - June 2020 (LTM): Peer Snapshot

Peer Snapshot:  Amgen Inc. - June 2020 (LTM) 4 September 2020 (in US millions) FYE Dec-18 FYE Dec-19 LTM Jun-20 FYE Dec-18 FYE Dec-19 LTM Jun-20 FYE Dec-18 FYE Dec-19 LTM Jun-20

AMGEN sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of AMGEN (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date January 15, 2021, the closing price was USD 245.49 and its potential was estimated at USD 264.50.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch